Spaventa Andrew 4
4 · Singular Genomics Systems, Inc. · Filed Nov 13, 2024
Insider Transaction Report
Form 4
Spaventa Andrew
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2024-11-12−1,907→ 24,780 total→ Common Stock (1,907 underlying) - Exercise/Conversion
Common Stock
2024-11-12+1,907→ 2,232 total - Gift
Common Stock
2024-11-12+1,212→ 141,487 total(indirect: By Trust) - Sale
Common Stock
2024-11-12$22.55/sh−695$15,669→ 1,537 total - Gift
Common Stock
2024-11-12−1,212→ 325 total
Holdings
- 85(indirect: By LLC)
Common Stock
Footnotes (6)
- [F1]Represents shares of Common Stock issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted RSUs.
- [F3]Immediately upon settlement of the vested RSUs, and following the withholding described above, the Reporting Person transferred the shares as a gift to The Andrew K. Spaventa Living Trust dated April 9, 2014.
- [F4]The shares are held directly by Axon Holdings, LLC. The managing member of Axon Holdings, LLC is Axon Managers, LLC. The Reporting Person is a managing member of Axon Managers, LLC and may be deemed to have shared voting and investment power over the shares held by Axon Holdings, LLC. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
- [F5]Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- [F6]The RSUs vest in 16 equal quarterly installments over four years measured from February 12, 2024.